MX2020012464A - Formulaciones de dantroleno y metodos de uso de dichas formulaciones. - Google Patents
Formulaciones de dantroleno y metodos de uso de dichas formulaciones.Info
- Publication number
- MX2020012464A MX2020012464A MX2020012464A MX2020012464A MX2020012464A MX 2020012464 A MX2020012464 A MX 2020012464A MX 2020012464 A MX2020012464 A MX 2020012464A MX 2020012464 A MX2020012464 A MX 2020012464A MX 2020012464 A MX2020012464 A MX 2020012464A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- formulations
- dantrolene
- dantrolene formulations
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862674394P | 2018-05-21 | 2018-05-21 | |
| PCT/US2019/033260 WO2019226621A1 (en) | 2018-05-21 | 2019-05-21 | Dantrolene formulations and methods of their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020012464A true MX2020012464A (es) | 2021-02-09 |
Family
ID=66821419
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020012464A MX2020012464A (es) | 2018-05-21 | 2019-05-21 | Formulaciones de dantroleno y metodos de uso de dichas formulaciones. |
| MX2025002392A MX2025002392A (es) | 2018-05-21 | 2020-11-19 | Formulaciones de dantroleno y metodos de uso de dichas formulaciones |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025002392A MX2025002392A (es) | 2018-05-21 | 2020-11-19 | Formulaciones de dantroleno y metodos de uso de dichas formulaciones |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210236467A1 (https=) |
| EP (1) | EP3796889A1 (https=) |
| JP (2) | JP7762489B2 (https=) |
| KR (1) | KR20210011961A (https=) |
| CN (1) | CN112135605A (https=) |
| AU (1) | AU2019272577B2 (https=) |
| BR (1) | BR112020023012A2 (https=) |
| CA (1) | CA3101093A1 (https=) |
| IL (1) | IL278575B1 (https=) |
| MA (1) | MA52707A (https=) |
| MX (2) | MX2020012464A (https=) |
| SG (1) | SG11202011121UA (https=) |
| UA (1) | UA127661C2 (https=) |
| WO (1) | WO2019226621A1 (https=) |
| ZA (1) | ZA202006986B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111419795A (zh) * | 2020-05-09 | 2020-07-17 | 上药东英（江苏）药业有限公司 | 一种注射用丹曲林钠混悬剂及其制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1361092A (en) | 1992-03-10 | 1993-10-05 | Kyukyu Pharmaceutical Co., Ltd. | Pharmaceutical preparation for percutaneous administration |
| JPH06263636A (ja) * | 1993-03-12 | 1994-09-20 | Kiyoshi Kataoka | 脳または高次神経疾患治療剤 |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| EP1603513B1 (en) * | 2003-03-04 | 2020-12-30 | Lyotropic Therapeutics, Inc. | Dantrolene compositions |
| WO2010126818A1 (en) * | 2009-04-27 | 2010-11-04 | Usworldmeds Llc | Intranasal delivery system for dantrolene |
| WO2019175761A1 (en) * | 2018-03-12 | 2019-09-19 | Orbicular Pharmaceutical Technologies Private Limited | Ready to use dantrolene compositions |
-
2019
- 2019-05-21 AU AU2019272577A patent/AU2019272577B2/en active Active
- 2019-05-21 MX MX2020012464A patent/MX2020012464A/es unknown
- 2019-05-21 BR BR112020023012-0A patent/BR112020023012A2/pt unknown
- 2019-05-21 SG SG11202011121UA patent/SG11202011121UA/en unknown
- 2019-05-21 KR KR1020207036289A patent/KR20210011961A/ko not_active Ceased
- 2019-05-21 EP EP19729994.4A patent/EP3796889A1/en active Pending
- 2019-05-21 JP JP2020564888A patent/JP7762489B2/ja active Active
- 2019-05-21 CN CN201980033640.3A patent/CN112135605A/zh active Pending
- 2019-05-21 US US17/052,572 patent/US20210236467A1/en not_active Abandoned
- 2019-05-21 MA MA052707A patent/MA52707A/fr unknown
- 2019-05-21 UA UAA202008098A patent/UA127661C2/uk unknown
- 2019-05-21 CA CA3101093A patent/CA3101093A1/en active Pending
- 2019-05-21 WO PCT/US2019/033260 patent/WO2019226621A1/en not_active Ceased
-
2020
- 2020-11-09 IL IL278575A patent/IL278575B1/en unknown
- 2020-11-10 ZA ZA2020/06986A patent/ZA202006986B/en unknown
- 2020-11-19 MX MX2025002392A patent/MX2025002392A/es unknown
-
2023
- 2023-11-10 JP JP2023191895A patent/JP2024023270A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019272577B2 (en) | 2024-08-08 |
| MA52707A (fr) | 2021-03-31 |
| JP2021524855A (ja) | 2021-09-16 |
| CN112135605A (zh) | 2020-12-25 |
| ZA202006986B (en) | 2024-04-24 |
| MX2025002392A (es) | 2025-04-02 |
| IL278575A (https=) | 2021-01-31 |
| IL278575B1 (en) | 2026-03-01 |
| UA127661C2 (uk) | 2023-11-22 |
| JP2024023270A (ja) | 2024-02-21 |
| CA3101093A1 (en) | 2019-11-28 |
| SG11202011121UA (en) | 2020-12-30 |
| AU2019272577A1 (en) | 2020-11-26 |
| BR112020023012A2 (pt) | 2021-02-02 |
| KR20210011961A (ko) | 2021-02-02 |
| JP7762489B2 (ja) | 2025-10-30 |
| EP3796889A1 (en) | 2021-03-31 |
| WO2019226621A1 (en) | 2019-11-28 |
| US20210236467A1 (en) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020000122A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| MX2024010140A (es) | Nuevos metodos. | |
| CL2019003126A1 (es) | Métodos de tratamiento mediante el uso de un compuesto inhibidor de jak. | |
| CL2018003291A1 (es) | Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018). | |
| MX2023011675A (es) | Beta-hidroxietilaminas heteroaril sustituidas para su uso en el tratamiento de hiperglucemia. | |
| MX2021002322A (es) | Nuevos metodos. | |
| CL2021001201A1 (es) | Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn | |
| MX2019009443A (es) | Metodos para tratar la influenza. | |
| MX2023000418A (es) | Fluorofenil beta-hidroxietilaminas y su uso en el tratamiento de la hiperglucemia. | |
| MA53973A (fr) | Inhibiteurs de la réplication du virus de l'immunodéficience humaine | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| AR099632A1 (es) | Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos | |
| PE20181345A1 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cancer | |
| MX2019001877A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
| MX2020011100A (es) | Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar. | |
| MX374724B (es) | Derivados de carbazol. | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| AR112144A1 (es) | Compuestos para el tratamiento del sarcoma | |
| CO2018005983A2 (es) | Compuestos de isoindol | |
| EP3957655A4 (en) | ETHYLENE VINYL ALCOHOL COPOLYMER AND AQUEOUS SOLUTION WITH USE THEREOF | |
| JOP20210051A1 (ar) | علاج للسرطان بواسطة استخدم توليفة من فيروس الوقس الحال للورم ومثبط نقاط الفحص المناعي، وتركيبة صيدلانية ودواء توليفي للاستخدام في علاج السرطان | |
| EA201791696A1 (ru) | Композиция для лечения веноокклюзионной болезни печени | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| ECSP22089498A (es) | Inhibidores de il4i1 y métodos de uso | |
| MX2018012739A (es) | Acetil-leucina o una sal farmaceuticamente aceptable de la misma para mejorar la movilidad y funcion cognitiva. |